The central role of arterial retention of cholesterolrich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: A triumph of simplicity

Current Opinion in Lipidology

Volumn 27, Issue 5, 2016, Pages 473-483

  Borén, Jan ^a,b   Williams, Kevin Jon ^a,b,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein B; Atherosclerosis; Mendelian randomization studies; Prospective randomized controlled trials; Proteoglycan

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; PROTEIN AGGREGATE;

ARTERY WALL; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE EXACERBATION; HUMAN; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ARTERY; ATHEROSCLEROSIS; CHEMISTRY; METABOLISM; RISK FACTOR;

ANIMALS; APOLIPOPROTEINS B; ARTERIES; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; PROTEIN AGGREGATES; RISK FACTORS;

EID: 84987810600     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000330     Document Type: Review

References (102)

1. Mihaylova B, Emberson J, Blackwell L, et al., Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-Analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387- 2397.
3. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489- 1499.
4. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509.
5. Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein- lowering therapy and cardiovascular risk reduction-statement from ATVB Council. Arterioscler Thromb Vasc Biol 2015; 35:2269-2280.
6. Williams KJ, Tabas I, Fisher EA. How an artery heals. Circ Res 2015; 117:909-913.
7. Steinberg D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res 2004; 45:1583-1593.
8. Capron L. Pathogenie de l'atherosclerose: mises à jour des trois theories dominantes. Ann Cardiol Angeiol (Paris) 1989; 38:631-634.
9. Williams KJ, Tabas I. The response-To-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
10. Ventura HO. Profiles in cardiology. Rudolph Virchow and cellular pathology. Clin Cardiol 2000; 23:550-552.
11. Williams KJ, Tabas I. Lipoprotein retention -And clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005; 25:1536-1540.
12. Anitschkow N, Chalatow S. Ü ber experimentelle Cholesterinsteatose und ihre Bedeutung fü r die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat 1913; 24:1-9.
13. Konstantinov IE, Mejevoi N, Anichkov NM, Nikolai N. Anichkov and his theory of atherosclerosis. Tex Heart Inst J 2006; 33:417-423.
14. Faber M. The human aorta; sulfate-containing polyuronides and the deposition of cholesterol. Arch Pathol (Chic) 1949; 48:342-350.
15. Camejo G, Lopez A, Vegas H, Paoli H. The participation of aortic proteins in the formation of complexes between low density lipoproteins and intimamedia extracts. Atherosclerosis 1975; 21:77-91.
16. Iverius P-H. The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. J Biol Chem 1972; 247:2607-2613.
17. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Interaction of serum lipoproteins and a proteoglycan from bovine aorta. J Biol Chem 1981; 256:8234-8241.
18. Smith EB, Slater RS. Lipids and low density lipoproteins in intima in relation to its morphological characteristics. Ciba Found Symp 1973; 12:39-62.
19. Tamminen M, Mottino G, Qiao JH, et al. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19:847-853.
20. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterolfed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 1989; 9:908- 918.
21. Nakashima Y, Fujii H, Sumiyoshi S, et al. Early human atherosclerosis: Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007; 27:1159- 1165.
22. Borén J, Gustafsson M, Skalén K, et al. Role of extracellular retention of low density lipoproteins in atherosclerosis. Curr Opin Lipidol 2000; 11:451- 456.
23. Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res 1987; 28:225-237.
24. Frank PG, Pavlides S, Cheung MW, et al. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol 2008; 295:C242- C248.
25. Fernández-Hernando C, Yu J, Suárez Y, et al. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab 2009; 10:48-54.
26. Armstrong SM, Sugiyama MG, Fung KY, et al. A novel assay uncovers an unexpected role for SR-BI in LDL transcytosis. Cardiovasc Res 2015; 108:268-277.
27. Kraehling JR, Rajagopal C, Sessa WC. Identification of novel mechanisms of LDL uptake into endothelium. Naunyn-Schmiedeberg's Arch Pharmacol 2014; 387 (Suppl1):S12;.
28. Nielsen LB, Stender S, Jauhiainen M, Nordestgaard BG. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest 1996; 98:563-571.
29. Nielsen LB, Gronholdt ML, Schroeder TV, et al. In vivo transfer of lipoprotein( a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997; 17:905-911.
30. Bartels ED, Christoffersen C, Lindholm MW, Nielsen LB. Altered metabolism of LDL in the arterial wall precedes atherosclerosis regression. Circ Res 2015; 117:933-942.
31. Tran-Lundmark K, Tran PK, Paulsson-Berne G, et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: Roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res 2008; 103: 43-52.
32. Borén J, Olin K, Lee I, et al. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101:2658-2664.
33. Flood C, Gustafsson M, Richardson PE, et al. Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 2002; 277:32228- 32233.
34. Camejo G, Fager G, Rosengren B, et al. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 1993; 268:14131-14137.
35. Tannock LR. Proteoglycan-LDL interactions: A novel therapeutic target? Atherosclerosis 2014; 233:232-233.
36. Skalén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750- 754.
37. Vikramadithyan RK, Kako Y, Chen G, et al. Atherosclerosis in perlecan heterozygous mice. J Lipid Res 2004; 45:1806-1812.
38. Huang F, Thompson JC, Wilson PG, et al. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res 2008; 49:521-530.
39. Tang T, Wilson PG, Thompson JC, et al. Prevention of TGFß induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice. J Lipid Res 2013; 54:2255-2264.
40. She ZG, Chang Y, Pang HB, et al. NG2 ablation reduces low-density lipoprotein retention of synthetic smooth muscle cells and atherogenesis. Arterioscler Thromb Vasc Biol 2016; 36:49-59.
41. Fogelstrand P, Borén J. Catch and release: NG2-coated vascular smooth muscle cells capture lipoproteins for macrophages. Arterioscler Thromb Vasc Biol 2016; 36:7-8.
42. Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group V secretory phospholipase A2 promotes atherosclerosis: Evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007; 27:600-606.
43. Öörni K, Kovanen PT. PLA2-V: A real player in atherogenesis. Arterioscler Thromb Vasc Biol 2007; 27:445-447.
44. Gustafsson M, Levin M, Skalén K, et al. Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: Evidence for a role of lipoprotein lipase. Circ Res 2007; 101:777-783.
45. Devlin CM, Leventhal AR, Kuriakose G, et al. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008; 28:1723-1730.
46. RuuthM, Nguyen SD, Vihervaara T, et al. Unstable LDL - novel mechanism of atherogenesis and link to cardiovascular deaths. 15 April 2016, Krogerup Højskole, Humlebæk, Denmark: Oral presentation at the 22nd annual Scandinavian atherosclerosis conference, Scandinavian Society for Atherosclerosis Research (SSAR); 2016.
47. Coronado-Gray A, van Antwerpen R. The physical state of the LDL core influences the conformation of apolipoprotein B-100 on the lipoprotein surface. FEBS Lett 2003; 533:21-24.
48. Melchior JT, Sawyer JK, Kelley KL, et al. LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis. J Lipid Res 2013; 54:2495-2503.
49. Flood C, Gustafsson M, Pitas RE, et al. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 2004; 24:564-570.
50. Borén J, Watts GF, AdielsM, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol 2015; 35:2218-2224.
51. Olin-Lewis K, Krauss RM, La Belle M, et al. ApoC-III content of apoBcontaining lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002; 43:1969-1977.
52. Davidsson P, Hulthe J, Fagerberg B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005; 46:1999-2006.
53. Hiukka A, Stahlman M, Pettersson C, et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009; 58:2018-2026.
54. Didangelos A, Mayr U, Monaco C, Mayr M. Novel role of ADAMTS-5 in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem 2012; 287:19341-19345.
55. Seidelmann SB, Kuo C, Pleskac N, et al. Athsq1 is an atherosclerosis modifier locus with dramatic effects on lesion area and prominent accumulation of versican. Arterioscler Thromb Vasc Biol 2008; 28:2180-2186.
56. Tang T, Thompson JC, Wilson PG, et al. Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection. J Mol Cell Cardiol 2014; 75:174-180.
57. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: Role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 2008; 79:14-23.
58. Maus F, Sakry D, Biname F, et al. The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2. PLoS One 2015; 10:e0137311.
59. Matsumoto H, Kumon Y, Watanabe H, et al. Accumulation of macrophagelike cells expressing NG2 proteoglycan and Iba1 in ischemic core of rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 2008; 28:149-163.
60. Peiffer V, Sherwin SJ, Weinberg PD. Does low and oscillatory wall shear stress correlate spatially with early atherosclerosis? A systematic review. Cardiovasc Res 2013; 99:242-250.
61. Kwak BR, Bäck M, Bochaton-Piallat ML, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J 2014; 35:3013-3020. [ESC Position Paper].
62. Steffensen LB, Mortensen MB, Kjolby M, et al. Disturbed laminar blood flow vastly augments lipoprotein retention in the artery wall: A key mechanism distinguishing susceptible from resistant sites. Arterioscler Thromb Vasc Biol 2015; 35:1928-1935.
63. Brito V, Mellal K, Portelance SG, et al. Induction of antianti-idiotype antibodies against sulfated glycosaminoglycans reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012; 32:2847-2854.
64. Delgado-Roche L, Brito V, Acosta E, et al. Arresting progressive atherosclerosis by immunization with an antiglycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice. Free Radic Biol Med 2015; 89:557-566.
65. Moreton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947; 106:190-191.
66. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation 1979; 60:473-485.
67. Williams KJ, Wu X. Imbalanced insulin action in chronic over nutrition: clinical harm, molecular mechanisms, and a way forward. Atherosclerosis 2016; 247:225-282.
68. Taskinen MR, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015; 239:483-495.
69. Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol 2010; 21:218-228.
70. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61:427-436.
71. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
72. Hassing HC, Mooij H, Guo S, et al. Inhibition of hepatic sulfatase-2 in vivo: A novel strategy to correct diabetic dyslipidemia. Hepatology 2012; 55:1746- 1753.
73. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370:1809-1819.
74. Holman RR, Koren MJ, Roth E, et al. Evaluation of the glycemic effects and efficacy and safety of evolocumab (AMG 145) in subjects with or without dysglycemia or metabolic syndrome. Diabetes 2015; 64 (suppl.1):A68; Oral presentation at the 75th Scientific Sessions of the American Diabetes Association, Chicago, IL, USA, 7 June 2015.
75. Tabas I, Li Y, Brocia RW, et al. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem 1993; 268:20419-20432.
76. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
77. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304- 1316.
78. Örni K, Rajamäki K, Nguyen SD, et al. Acidification of the intimal fluid: The perfect storm for atherogenesis. J Lipid Res 2015; 56:203-214.
79. Sneck M, Nguyen SD, Pihlajamaa T, et al. Conformational changes of apoB- 100 in SMase-modified LDL mediate formation of large aggregates at acidic pH. J Lipid Res 2012; 53:1832-1839.
80. Williams KJ, Fisher EA. Apolipoprotein-B: The crucial protein of atherogenic lipoproteins. In: Wang H, Patterson C, editors. Atherosclerosis: Risks, mechanisms, & therapies. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2015. pp. 291-312.
81. Deevska GM, Sunkara M, Morris AJ, Nikolova-Karakashian MN. Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/-mice fed on a high-fat diet. Biosci Rep 2012; 32:479-490.
82. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116:1832-1844.
83. Lao KH, Zeng L, Xu Q. Endothelial and smooth muscle cell transformation in atherosclerosis. Curr Opin Lipidol 2015; 26:449-456.
84. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol 2013; 13:709-721.
85. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008; 5:91-102.
86. Bracho-Sanchez E, Ramkhelawon B, Desvignes L, et al. Induction of neural guidance molecule expression in macrophages and dendritic cells by Mycobacterium tuberculosis. J Immunol 2013; 190 (Suppl1):55.9.
87. Williams KJ. What does HDL do? A new mechanism to slow atherogenesis - but a new problem in type 2 diabetes mellitus. Atherosclerosis 2012; 225:36-38.
88. Hewing B, Moore KJ, Fisher EA. HDL and cardiovascular risk: Time to call the plumber? Circ Res 2012; 111:1117-1120.
89. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 2012; 380:572-580.
90. Bihari-Varga M. Influence of serum high density lipoprotein on the low density lipoprotein-Aortic glycosaminoglycan interactions. Artery 1978; 4:504-509.
91. Camejo G, Cortez MM, Lopez F, et al. Factors modulating the interaction of LDL with an arterial lipoprotein complexing proteoglycan: The effect of HDL. Acta Med Scand Suppl 1980; 642:159-164.
92. Umaerus M, Rosengren B, Fagerberg B, et al. HDL2 interferes with LDL association with arterial proteoglycans: A possible athero-protective effect. Atherosclerosis 2012; 225:115-120.
93. Schissel SL, Tweedie-Hardman J, Rapp JH, et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98:1455-1464.
94. De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates antiinflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014; 15:152-160.
95. Moore KJ, Fisher EA. High-density lipoproteins put out the fire. Cell Metab 2014; 19:175-176.
96. Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidase- modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2014; 34:779-789.
97. Niyonzima N, Samstad EO, Aune MH, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J Immunol 2015; 195:257-264.
98. Bursill CA, Castro ML, Beattie DT, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010; 30:1773-1778.
99. Nguyen SD, Javanainen M, Rissanen S, et al. Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J Lipid Res 2015; 56:1206-1221.
100. Chiba T, Chang MY, Wang S, et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 2011; 31:1326-1332.
101. Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014; 20:193- 203.
102. Nicholls S, Ray K, Ballantyne C, et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin and ezetimide therapy on atherogenic and protective lipid factors: The Accentuate Trial. Innsbruck: 84th European Atherosclerosis Society Congress; 2016.